Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI5752 in TLS+ Advanced Solid Tumors
NCT05888857Phase 2Not yet recruiting
- Sponsor
- Institut Bergonié
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of volrustomig in solid tumor (advanced stage) (2 cohorts), sponsored by Institut Bergonié. Primary endpoint: Assessment of the antitumor activity of MEDI5752 at 6 months. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
volrustomig
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05888857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05888857.